Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG Vaccine for Non-specific Protection in Seniors (BCG-DENMARK-SENIOR)
NCT04542330Phase 3Completed
- Sponsor
- Bandim Health Project
- Start
- Sep 2020
- Primary completion
- Jan 2023
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bacillus calmette-guerin substrain danish 1331 live antigen in coronavirus disease 2019 (COVID-19), acute infection and respiratory tract infection (RTI) (2 arms), sponsored by Bandim Health Project. Primary endpoint: Acute Infection at 12 months. Started Sep 2020; status: completed.
02
Drugs
bacillus calmette-guerin substrain danish 1331 live antigen
03
Conditions
coronavirus disease 2019 (COVID-19)acute infectionrespiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT04542330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542330.